Essex Bio-Technology Ltd
HKEX:1061
Essex Bio-Technology Ltd
HKEX:1061
Price:
4.28
HKD
Market Cap:
HK$2.4B
Relative Value
The Relative Value of one
Essex Bio-Technology Ltd
stock under the Base Case scenario is
6.52
HKD.
Compared to the current market price of 4.28 HKD,
Essex Bio-Technology Ltd
is
Undervalued by 34%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Relative Value
Base Case
6.52
HKD
Undervaluation 34%
Multiples Across Competitors
Competitors Multiples
Essex Bio-Technology Ltd Competitors
Essex Bio-Technology Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| HK |
|
Essex Bio-Technology Ltd
HKEX:1061
|
2.4B HKD | 1.4 | 7.7 | 4.5 | 5.1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 643 258.8 | -159 901.4 | -194 171.3 | -191 955.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
395.5B USD | 6.6 | 168.3 | 16.3 | 23.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
198.2B USD | 5.4 | 25.5 | 14.7 | 14.7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
184.1B USD | 6.3 | 22.7 | 15.4 | 15.4 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
118.1B USD | 10.1 | 32.1 | 23.6 | 24.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 094 | -534.3 | -581.8 | -566.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.5B USD | 5.5 | 17.7 | 14.9 | 17 | |
| AU |
|
CSL Ltd
ASX:CSL
|
77.8B AUD | 3.5 | 18 | 12.2 | 15.3 | |
| NL |
|
argenx SE
XBRU:ARGX
|
43.4B EUR | 14.3 | 33.7 | 57.5 | 59.1 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.2 | -61.8 | -66.7 | -60.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
